Lexaria Bioscience (LEXX.Q) announced today that dosing has been completed for its HYPER-H21-2 study, the Company’s second human clinical study of 2021. Hypertension, also known as high blood…
Pharmaceuticals
Oragenics Inc. (OGEN.NYSE) announced today that it has entered into a licensing agreement with the National Research Council of Canada (NRC). “With respect to our potential future competitive positioning…
Iterum Therapeutics (ITRM.Q) announced today that it has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for its New Drug Application (NDA). Iterum…
Tyme Technologies (TYME.Q) announced today that the United States Patent and Trademark Office has granted the Company additional patent claims related to the Company’s metabolomic technology platform. …
Acorda Therapeutics (ACOR.Q) announced today that it has entered into a distribution and supply agreement with Esteve Pharmaceuticals to commercialize INBRIJA® 33 mg in Spain. “We are…
Aprea Therapeutics (APRE.Q) today announced positive results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant MDS and AML. “The…
Lexaria Bioscience (LEXX.Q) announced today that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. The VIRAL-A20-3 study was performed using Sprague-Dawley rats, with…
MediWound (MDWD.Q), a biopharmaceutical company focused on developing solutions for tissue repair and regeneration, today announced positive topline results from its pivotal phase 3 pediatric clinical study (CIDS – Children…
GlaxoSmithKline (GSK.NYSE) today announced positive headline results from five studies of the Phase 3 ASCEND program, evaluating the efficacy and safety profile of daprodustat, an investigational oral hypoxia-inducible factor…
Revive Therapeutics (RVV.C) has provided an update on the Company’s US Food and Drug Administration (FDA) Phase 3 clinical trial to evaluate the safety and efficacy of bucillamine in…